Stockscreener 앱 받기
23.13
0.73%
-0.17
전일 마감가:
$23.30
열려 있는:
$22.8
하루 거래량:
8.15M
Relative Volume:
1.03
시가총액:
$16.09B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
4.0938
EPS:
5.65
순현금흐름:
$-781.21M
1주 성능:
+5.23%
1개월 성능:
+0.83%
6개월 성능:
+100.43%
1년 성능:
+112.40%
1일 변동 폭
$22.15
$23.20
1주일 범위
$21.57
$23.91
52주 변동 폭
$8.73
$23.91
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
ROIV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
23.13 | 16.20B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences Insider Sold Shares Worth $4,384,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences(ROIV.US) Officer Sells US$4.38 Million in Common Stock - 富途牛牛
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Is Roivant Sciences Ltd forming a bullish divergenceJuly 2025 Technicals & Long-Term Growth Stock Strategies - baoquankhu1.vn
Roivant Sciences stock hits all-time high of $23.47 By Investing.com - Investing.com Nigeria
US Market Wrap: Does Roivant Sciences Ltd stock trade at a discount to peers2025 Technical Overview & Stepwise Entry and Exit Trade Signals - Bộ Nội Vụ
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighWhat's Next? - MarketBeat
Discipline and Rules-Based Execution in ROIV Response - Stock Traders Daily
Why Roivant Sciences Ltd. stock could be next big winnerJuly 2025 Sentiment & Low Risk High Reward Ideas - Bộ Nội Vụ
Roivant Sciences stock hits all-time high of $23.47 - Investing.com India
Profit Recap: How risky is Roivant Sciences Ltd stock nowJuly 2025 Highlights & Real-Time Sentiment Analysis - Bộ Nội Vụ
Proxima Raises $80 Million for AI Drug Discovery From DCVA, Nvidia - Bloomberg.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 22.84% Potential Upside in Biotech Innovations - DirectorsTalk Interviews
Buyback Watch: Whats the fair value of Roivant Sciences Ltd stockTrade Ideas & Risk Controlled Daily Plans - baoquankhu1.vn
Published on: 2026-01-10 23:30:08 - Улправда
How Roivant Sciences Ltd. (87S) stock reacts to fiscal policiesJuly 2025 Sentiment & Verified Entry Point Signals - Улправда
What margin trends mean for Roivant Sciences Ltd. stock2025 Historical Comparison & Fast Entry Momentum Trade Alerts - Улправда
Aug Ideas: Can NETGEAR Inc stock maintain operating marginsVolume Spike & Weekly Top Performers Watchlists - moha.gov.vn
Can Roivant Sciences Ltd. stock double in next 5 yearsMarket Performance Summary & Weekly Stock Breakout Alerts - Улправда
How Roivant Sciences Ltd. stock reacts to global recession fears2025 Big Picture & Community Supported Trade Ideas - Улправда
Is Roivant Sciences Ltd. stock positioned for digital transformation2025 Investor Takeaways & Target Return Focused Stock Picks - Улправда
How Roivant Sciences Ltd. stock performs in rate cut cyclesWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Aug Big Picture: How Roivant Sciences Ltd. stock reacts to global recession fearsWeekly Earnings Recap & Real-Time Volume Surge Alerts - ulpravda.ru
What Roivant Sciences (ROIV)'s Accelerated Brepocitinib Push Means For Shareholders - simplywall.st
A Look At Roivant Sciences (ROIV) Valuation After Brepocitinib Timeline Acceleration And Profitability Outlook Shift - simplywall.st
Leerink Partners reiterates Outperform rating on Roivant Sciences stock By Investing.com - Investing.com South Africa
Leerink raises price target as Roivant (ROIV) accelerates drug development pipeline - MSN
Psithera spun out of Roivant with $47.5M and immune, inflammatory focus - BioWorld MedTech
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Penn Davis Mcfarland Inc. Buys 170,456 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Pacer Advisors Inc. Makes New Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline - Insider Monkey
Roivant Sciences Insider Sold Shares Worth $28,902,500, According to a Recent SEC Filing - MarketScreener
Book value per share of Roivant Sciences Ltd. – DUS:87S - TradingView — Track All Markets
Mayukh Sukhatme Sells 1,018,995 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Mayukh Sukhatme Sells 311,873 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Drops By 16.2% - MarketBeat
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 75,000 Shares of Stock - MarketBeat
Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences Executives Engage in Significant Share Sales - TradingView — Track All Markets
Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Capricorn Fund Managers Ltd Buys New Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Insider Confidence In December 2025's Leading Growth Companies - Yahoo! Finance Canada
Reassessing Roivant Sciences (ROIV) Valuation After Pipeline Progress, NDA Timelines and Genevant Litigation Updates - simplywall.st
Voya Investment Management LLC Grows Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Is Roivant Sciences Ltd stock positioned for digital transformationGap Down & High Conviction Trade Alerts - moha.gov.vn
Ramaswamy-Backed Ambros Launches with $125M - Orange County Business Journal
Roivant Sciences president Sukhatme sells $619k in shares By Investing.com - Investing.com Australia
Roivant Sciences president Sukhatme sells $619k in shares - Investing.com UK
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Roivant Sciences Ltd 주식 (ROIV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Jan 12 '26 |
Sale |
21.92 |
200,000 |
4,384,000 |
1,654,597 |
4.73%
0.92%
자본화:
|
볼륨(24시간):